Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients*. Issue 2 (20th January 2023)

• Record Type: Journal Article
• Authors: Friedrich, Jan O.; Harhay, Michael O.; Angus, Derek C.; Burns, Karen E. A.; Cook, Deborah J.; Fergusson, Dean A.; Finfer, Simon; Hébert, Paul; Rowan, Kathy; Rubenfeld, Gordon; Marshall, John C.
• Is Part Of: Critical care medicine. Volume 51:Issue 2(2023)
• Page Start: 222
• Page End: 230
• Publication Date: 2023-01-20
• Subjects: ARDS -- critical care -- mortality -- sepsis -- trials; Critical care medicine -- Periodicals; Soins intensifs -- Périodiques; 616.028
• DOI: 10.1097/CCM.0000000000005721
• Languages: English
• ISSNs: 0090-3493

Abstract

Abstract : OBJECTIVES: All-cause mortality is a common measure of treatment effect in ICU-based randomized clinical trials (RCTs). We sought to understand the performance characteristics of a mortality endpoint by evaluating its temporal course, responsiveness to differential treatment effects, and impact when used as an outcome measure in trials of acute illness. DATA SOURCES: We searched OVID Medline for RCTs published from 1990 to 2018. STUDY SELECTION: We reviewed RCTs that had randomized greater than or equal to 100 patients, were published in one of five high-impact general medical or eight critical care journals, and reported mortality at two or more distinct time points. We excluded trials recruiting pediatric or neonatal patients and cluster RCTs. DATA EXTRACTION: Mortality by randomization group was recorded from the article or estimated from survival curves. Trial impact was assessed by inclusion of results in clinical practice guidelines. DATA SYNTHESIS: From 2, 592 potentially eligible trials, we included 343 RCTs (228, 784 adult patients). While one third of all deaths by 180 days had occurred by day 7, the risk difference between study arms continued to increase until day 60 ( p = 0.01) and possibly day 90 ( p = 0.07) and remained stable thereafter. The number of deaths at ICU discharge approximated those at 28–30 days (95% [interquartile range [IQR], 86–106%]), and deaths at hospital discharge approximated those at 60 days (99% [IQR, 94–104%]). Only 13 of 43 interventions (30.2%) showing a mortality benefit have been adopted into widespread clinical practice. CONCLUSIONS: Our findings provide a conceptual framework for choosing a time horizon and interpreting mortality outcome in trials of acute illness. Differential mortality effects persist for 60 to 90 days following recruitment. Location-based measures approximate time-based measures for trials conducted outside the United States. The documentation of a mortality reduction has had a modest impact on practice.